The UK-based firm is developing its initial panel tests for Gram-negative bacteria with tests for Gram-positive bacteria and ...

The test will measure levels of the 14-3-3eta protein, which is used in the diagnosis and management of inflammatory diseases including rheumatoid arthritis.

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.

The Gram-positive blood culture assay is the firm's third panel for the detection and identification of bloodstream pathogens using the Liaison Plex instrument.

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

The certification is for products used in hematology instruments manufactured globally, including instruments from Abbott, Beckman Coulter, and Siemens Healthineers.

NEW YORK – Autoimmune testing firm Exagen on Tuesday announced its Q3 revenues declined 7 percent year over year. For the three months ended Sept. 30, the firm posted revenues of $12.5 million, down ...

NEW YORK – Lumea and Caris Life Sciences said on Thursday that they have agreed to make Caris' sequencing-based urology tools available through Lumea's BxLink digital pathology platform. Under the ...

NEW YORK – AI diagnostics firm Tempus said on Tuesday that it has inked a deal with Roche's Flatiron Health that will allow healthcare providers to order Tempus' genomic cancer tests through ...